BP PLC continued to hold its position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 166,000 shares of the medical equipment provider’s stock at the end of the second quarter. BP PLC’s holdings in Boston Scientific Corporation were worth $4,600,000 at the end of the most recent reporting period.
Several other institutional investors have also recently made changes to their positions in the stock. Advisor Partners LLC boosted its stake in Boston Scientific Corporation by 24.9% in the second quarter. Advisor Partners LLC now owns 27,060 shares of the medical equipment provider’s stock valued at $750,000 after buying an additional 5,396 shares in the last quarter. Pictet Asset Management Ltd. boosted its stake in shares of Boston Scientific Corporation by 4.6% in the second quarter. Pictet Asset Management Ltd. now owns 1,275,775 shares of the medical equipment provider’s stock valued at $34,484,000 after buying an additional 56,098 shares during the period. Goelzer Investment Management Inc. acquired a new stake in shares of Boston Scientific Corporation during the second quarter valued at approximately $2,117,000. Retirement Systems of Alabama boosted its stake in shares of Boston Scientific Corporation by 0.3% in the second quarter. Retirement Systems of Alabama now owns 1,404,418 shares of the medical equipment provider’s stock valued at $38,930,000 after buying an additional 4,875 shares during the period. Finally, IFP Advisors Inc boosted its stake in shares of Boston Scientific Corporation by 30.4% in the second quarter. IFP Advisors Inc now owns 9,077 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 2,114 shares during the period. 91.62% of the stock is owned by institutional investors.
Boston Scientific Corporation (BSX) opened at 26.89 on Friday. The company has a 50-day moving average of $27.16 and a 200 day moving average of $26.15. The company has a market cap of $36.90 billion, a P/E ratio of 48.10 and a beta of 1.09. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51.
Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the business earned $0.27 EPS. The firm’s revenue was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/bp-plc-holds-stake-in-boston-scientific-corporation-nysebsx-updated.html.
BSX has been the topic of several analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price target on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Boston Scientific Corporation in a research report on Tuesday, May 16th. They set a “neutral” rating and a $28.00 price target on the stock. Oppenheimer Holdings, Inc. set a $27.00 target price on shares of Boston Scientific Corporation and gave the company a “hold” rating in a report on Friday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price (up from $29.00) on shares of Boston Scientific Corporation in a report on Thursday, April 27th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $31.00 target price (up from $27.00) on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $30.06.
In other Boston Scientific Corporation news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $28.02, for a total transaction of $434,310.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP John Bradley Sorenson sold 7,900 shares of the stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total transaction of $208,323.00. Following the sale, the senior vice president now directly owns 21,680 shares of the company’s stock, valued at $571,701.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 207,625 shares of company stock worth $5,686,383. 0.74% of the stock is owned by company insiders.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.